secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001157523-21-001027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing
------------------------------------------------------------------------

- Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.
- Cash and marketable securities of $299M as of June 30, 2021, funding pipeline through key milestones.
- EDG-5506 Phase 1 MAD study ongoing; topline data from healthy volunteers and Becker patients expected late 2021.
- Preclinical EDG-002 cardiac modulator for hypertrophic cardiomyopathy progressing with encouraging data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/0001157523-21-001027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/a52473423.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-001027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer